Editas Medicine Inc
$ 2.88
-0.69%
07 Aug - close price
- Market Cap 442,310,000 USD
- Current Price $ 2.88
- High / Low $ 3.09 / 2.87
- Stock P/E N/A
- Book Value 0.28
- EPS -0.66
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.27 %
- ROE -3.26 %
- 52 Week High 4.54
- 52 Week Low 1.66
About
Editas Medicine, Inc., a clinical-stage genome editing company, is focused on developing transformative genomic drugs to treat a variety of serious diseases. The company is headquartered in Cambridge, Massachusetts.
Analyst Target Price
$6.00
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-08-05 | 2026-05-05 | 2026-03-09 | 2025-11-10 | 2025-08-12 | 2025-05-12 | 2025-03-05 | 2024-11-04 | 2024-08-07 | 2024-05-08 | 2024-02-28 | 2023-11-03 |
| Reported EPS | -0.15 | -0.26 | -0.06 | -0.28 | -0.32 | -0.92 | -0.55 | -0.75 | -0.82 | -0.76 | -0.23 | -0.55 |
| Estimated EPS | -0.3 | -0.24 | -0.2302 | -0.38 | -0.38 | -0.59 | -0.3286 | -0.77 | -0.71 | -0.64 | -0.54 | -0.58 |
| Surprise | 0.15 | -0.02 | 0.1702 | 0.1 | 0.06 | -0.33 | -0.2214 | 0.02 | -0.11 | -0.12 | 0.31 | 0.03 |
| Surprise Percentage | 50% | -8.3333% | 73.9357% | 26.3158% | 15.7895% | -55.9322% | -67.3767% | 2.5974% | -15.493% | -18.75% | 57.4074% | 5.1724% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: EDIT
2026-08-08 05:41:20
Wall Street Zen has upgraded Editas Medicine (NASDAQ:EDIT) from "sell" to "hold." Despite this, broader analyst coverage remains "Moderate Buy" with a consensus price target of $5.40. The company recently surpassed quarterly earnings and revenue expectations, although company insiders have sold shares while institutional investors, including BlackRock, have significantly increased their holdings.
2026-08-08 02:09:43
Editas Medicine director Ellinor Patrick Thomas II has filed an initial beneficial ownership statement (Form 3) with the SEC, dated August 6. This filing indicates that Thomas is now a reporting owner for the company. The news brief was generated by Public Technologies (PUBT) using AI and is based on original content filed by Editas Medicine Inc. via EDGAR.
2026-08-07 21:41:20
Editas Medicine (NASDAQ: EDIT) reported that director Ellinor Patrick Thomas II was granted 103,400 stock options with an exercise price of $2.9000 per share, expiring on August 5, 2036. These options vest in three equal annual installments starting August 6, 2027. Following this grant, the director directly holds 103,400 derivative securities.
2026-08-07 21:41:20
A director at Editas Medicine, Inc. (EDIT), Ellinor Patrick Thomas II, has filed an initial beneficial ownership report (Form 3) disclosing no holdings of common stock or derivative securities. The filing indicates no insider transaction activity, such as purchases or sales, associated with this individual. Ellinor Patrick Thomas II is identified solely as a director, not as an officer or a ten percent owner.
2026-08-07 15:09:55
Editas Medicine (EDIT) saw its stock rally by about 5% after reporting Q2 2026 earnings, driven by a significant increase in revenue to US$11.89 million from US$3.58 million year-on-year. While the company is still reporting losses, these narrowed to US$18.23 million from US$53.24 million, and basic EPS loss decreased to US$0.15 from US$0.63. Despite this positive momentum, the article notes that funding risks and volatility remain concerns for the clinical-stage biotech.
2026-08-06 15:09:56
Editas Medicine, Inc. reported an increase in collaboration and research revenue to $11.89M for the quarter ended 2026, with a reduced net loss of ($18.23M) and improved diluted EPS of ($0.15). Key highlights include the nomination of EDIT-401 as the lead in vivo candidate with a Phase 1/2 trial planned, and successful equity offering to fund operations into the second half of 2028. The company has also narrowed its R&D priorities and completed workforce reductions.
